Bionomics

A screen displaying stock prices

Biotech

Bionomics' midphase PTSD clinical trial hits primary endpoint

Investors sent Bionomics' share price up almost 100% on the strength of phase 2 data in post-traumatic stress disorder.

Nick Paul Taylor Sep 28, 2023 7:08am

Public speaking presentation speech questions seminar

Bionomics' lead asset fails to reduce public speaking anxiety

Dec 19, 2022 9:00am

chutes and ladders chutes

Roche's executive dominoes continue to tip—Chutes & Ladders

Dec 16, 2022 9:30am